Cargando…
Time for a lead-time definition? Author response to ‘Why the length of recurrence free survival or “lead-times” can be misleading. Comment on: Callesen LB, Takacova T, Hamfjord J, et al. Circulating DNA in patients undergoing loco-regional treatment of colorectal cancer metastases: a systematic review and meta-analysis’
Autores principales: | Spindler, Karen-Lise Garm, Callesen, Louise Bach, Arnold, Dirk |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026177/ https://www.ncbi.nlm.nih.gov/pubmed/36950273 http://dx.doi.org/10.1177/17588359231156393 |
Ejemplares similares
-
Why the length of recurrence-free survival or ‘lead-times’ can be
misleading. Comment on: Callesen LB, Takacova T, Hamfjord J, et
al. Circulating DNA in patients undergoing loco-regional treatment
of colorectal cancer metastases: a systematic review and
meta-analysis
por: Sorscher, Steven
Publicado: (2023) -
Estimated dose to site of loco-regional recurrence after radiotherapy in anal cancer using point of origin methods
por: Lycke Wind, Karen, et al.
Publicado: (2023) -
COVID-19 phenotypes: leading or misleading?
por: Gattinoni, Luciano, et al.
Publicado: (2020) -
Circulating cell-free DNA as predictor of pathological complete response in locally advanced rectal cancer patients undergoing preoperative chemoradiotherapy
por: Truelsen, Christina Glismand, et al.
Publicado: (2022) -
Circulating DNA and frequency of colorectal cancer brain metastases in a presumed high-risk group
por: Callesen, Louise Bach, et al.
Publicado: (2023)